Amikacin
- Generic Name
- Amikacin
- Brand Names
- Arikayce, Arikayce liposomal
- Drug Type
- Small Molecule
- Chemical Formula
- C22H43N5O13
- CAS Number
- 37517-28-5
- Unique Ingredient Identifier
- 84319SGC3C
- Background
Amikacin is a semi-synthetic aminoglycoside antibiotic that is derived from kanamycin A. Amikacin is synthesized by acylation with the l-(-)-γ-amino-α-hydroxybutyryl side chain at the C-1 amino group of the deoxystreptamine moiety of kanamycin A.
...
- Indication
The amikacin sulfate injection is indicated in the short-term treatment of serious bacterial infections due to susceptible strains of gram-negative bacteria, including Pseudomonas species, Escherichia coli, species of indole-positive and indole-negative Proteus, Providencia species, Klebsiella-Enterobacter-Serratia species, as well as Acinetobacter (Mima-Her...
- Associated Conditions
- Bacterial Peritonitis, Bone and Joint Infections, Burns, Central Nervous System Infections, Endophthalmitis, Infection caused by staphylococci, Infective pulmonary exacerbation of cystic fibrosis, Intraabdominal Infections, Meningitis, Bacterial, Mycobacterium avium complex infection, Neonatal Sepsis, Nosocomial Pneumonia, Postoperative Infections, Pulmonary Infections, Respiratory Tract Infection Bacterial, Sepsis Bacterial, Skin and Subcutaneous Tissue Bacterial Infections, Tuberculosis (TB), Grade 1, grade 2, grade 3, grade 4 Urinary Tract Infection, Severe Bacterial Infections
- Associated Therapies
- -
Insmed's Promising Pipeline and Strategic Readiness Drive Buy Rating
Jason Zemansky of Bank of America Securities reiterated a Buy rating on Insmed (INSM) with a raised price target to $90.00, citing progress in late-stage pipeline and commercial readiness. Insmed's Arikayce sales grew 18% YoY, and plans for NCFB's new drug application submission in Q4 were noted. Barclays also maintained a Buy rating with a $90.00 target. Corporate insider sentiment is negative due to increased insider selling.
Insmed's Q3 2024: Strong Growth and Strategic Advances
Insmed (INSM) reported Q3 2024 revenue of $93.4M, up 18% YoY, driven by ARIKAYCE sales growth. The company is on track for Brensocatib's U.S. launch in 2025, with an expanded U.S. sales force and improved financial terms. Insmed remains committed to 2024 ARIKAYCE revenue guidance and pipeline advancements.
Earnings call: Insmed reports strong Q3 growth, eyes brensocatib launch
Insmed reports strong Q3 2024 results, with global net revenues up 18% YoY to $93.4M, driven by ARIKAYCE sales growth. The company plans to file an NDA for brensocatib in Q4 2024, anticipating a mid-2025 launch. Insmed's U.S. sales force has expanded to 184 reps, and cash reserves stand at $1.5B. The company maintains full-year revenue guidance of $340M to $360M and expects peak sales for brensocatib to exceed $5B. Insmed is also advancing clinical trials for brensocatib in chronic rhinosinusitis and hidradenitis suppurativa, with results expected by late 2025.
Truist Securities raises Insmed stock price target as confidence grows in brensocatib launch
Truist Securities raised Insmed's price target to $100 from $85, retaining a Buy rating, following a survey on brensocatib's market potential. The survey's positive results led to an estimated peak sales increase to $8 billion. Insmed plans to file a New Drug Application for brensocatib in Q4 2024, with a mid-2025 launch anticipated. InvestingPro data supports Insmed's strong revenue growth and financial stability.
Risk Adjusted Net Present Value: What is the current valuation of Insmed's Treprostinil Palmitil
Treprostinil Palmitil, a drug under development for rare pulmonary disorders, is expected to generate $334 mn in annual revenue by 2037 in the US. Insmed, the biopharmaceutical company developing it, reported a net loss of $749.6 mn in FY2023. The drug's risk-adjusted NPV model (rNPV) considers the risk of failure in clinical development.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath